Searched for: in-biosketch:true
person:snudem01
A genome-wide association study of germline variation and melanoma prognosis
Chat, Vylyny; Dagayev, Sasha; Moran, Una; Snuderl, Matija; Weber, Jeffrey; Ferguson, Robert; Osman, Iman; Kirchhoff, Tomas
Background: The high mortality of cutaneous melanoma (CM) is partly due to unpredictable patterns of disease progression in patients with early-stage lesions. The reliable prediction of advanced disease risk from early-stage CM, is an urgent clinical need, especially given the recent expansion of immune checkpoint inhibitor therapy to the adjuvant setting. In our study, we comprehensively investigated the role of germline variants as CM prognostic markers. Methods: We performed a genome-wide association analysis in two independent cohorts of N=551 (discovery), and N=550 (validation) early-stage immunotherapy-naïve melanoma patients. A multivariable Cox proportional hazard regression model was used to identify associations with overall survival in the discovery group, followed by a validation analysis. Transcriptomic profiling and survival analysis were used to elucidate the biological relevance of candidate genes associated with CM progression. Results: We found two independent associations of germline variants with melanoma prognosis. The alternate alleles of these two SNPs were both associated with an increased risk of death [rs60970102 in MELK: HR=3.14 (2.05"“4.81), p=1.48×10-7; and rs77480547 in SH3BP4: HR=3.02 (2.02"“4.52), p=7.58×10-8, both in the pooled cohort]. The addition of the combined risk alleles (CRA) of the identified variants into the prognostic model improved the predictive power, as opposed to a model of clinical covariates alone. Conclusions: Our study provides suggestive evidence of novel melanoma germline prognostic markers, implicating two candidate genes: an oncogene MELK and a tumor suppressor SH3BP4, both previously suggested to affect CM progression. Pending further validation, these findings suggest that the genetic factors may improve the prognostic stratification of high-risk early-stage CM patients, and propose putative biological insights for potential therapeutic investigation of these targets to prevent aggressive outcome from early-stage melanoma.
SCOPUS:85147381623
ISSN: 2234-943x
CID: 5424662
Variant allelic frequency of driver mutations predicts success of genomic DNA methylation classification in central nervous system tumors
Jamshidi, Pouya; McCord, Matthew; Galbraith, Kristyn; Santana-Santos, Lucas; Jennings, Lawrence J; Snuderl, Matija; Horbinski, Craig
PMID: 36700952
ISSN: 1432-0533
CID: 5419672
Amplification of the PLAG-family genes-PLAGL1 and PLAGL2-is a key feature of the novel tumor type CNS embryonal tumor with PLAGL amplification
Keck, Michaela-Kristina; Sill, Martin; Wittmann, Andrea; Joshi, Piyush; Stichel, Damian; Beck, Pengbo; Okonechnikow, Konstantin; Sievers, Philipp; Wefers, Annika K; Roncaroli, Federico; Avula, Shivaram; McCabe, Martin G; Hayden, James T; Wesseling, Pieter; Øra, Ingrid; Nistér, Monica; Kranendonk, Mariëtte E G; Tops, Bastiaan B J; Zapotocky, Michal; Zamecnik, Josef; Vasiljevic, Alexandre; Fenouil, Tanguy; Meyronet, David; von Hoff, Katja; Schüller, Ulrich; Loiseau, Hugues; Figarella-Branger, Dominique; Kramm, Christof M; Sturm, Dominik; Scheie, David; Rauramaa, Tuomas; Pesola, Jouni; Gojo, Johannes; Haberler, Christine; Brandner, Sebastian; Jacques, Tom; Sexton Oates, Alexandra; Saffery, Richard; Koscielniak, Ewa; Baker, Suzanne J; Yip, Stephen; Snuderl, Matija; Ud Din, Nasir; Samuel, David; Schramm, Kathrin; Blattner-Johnson, Mirjam; Selt, Florian; Ecker, Jonas; Milde, Till; von Deimling, Andreas; Korshunov, Andrey; Perry, Arie; Pfister, Stefan M; Sahm, Felix; Solomon, David A; Jones, David T W
Pediatric central nervous system (CNS) tumors represent the most common cause of cancer-related death in children aged 0-14 years. They differ from their adult counterparts, showing extensive clinical and molecular heterogeneity as well as a challenging histopathological spectrum that often impairs accurate diagnosis. Here, we use DNA methylation-based CNS tumor classification in combination with copy number, RNA-seq, and ChIP-seq analysis to characterize a newly identified CNS tumor type. In addition, we report histology, patient characteristics, and survival data in this tumor type. We describe a biologically distinct pediatric CNS tumor type (n = 31 cases) that is characterized by focal high-level amplification and resultant overexpression of either PLAGL1 or PLAGL2, and an absence of recurrent genetic alterations characteristic of other pediatric CNS tumor types. Both genes act as transcription factors for a regulatory subset of imprinted genes (IGs), components of the Wnt/β-Catenin pathway, and the potential drug targets RET and CYP2W1, which are also specifically overexpressed in this tumor type. A derived PLAGL-specific gene expression signature indicates dysregulation of imprinting control and differentiation/development. These tumors occurred throughout the neuroaxis including the cerebral hemispheres, cerebellum, and brainstem, and were predominantly composed of primitive embryonal-like cells lacking robust expression of markers of glial or neuronal differentiation (e.g., GFAP, OLIG2, and synaptophysin). Tumors with PLAGL1 amplification were typically diagnosed during adolescence (median age 10.5 years), whereas those with PLAGL2 amplification were diagnosed during early childhood (median age 2 years). The 10-year overall survival was 66% for PLAGL1-amplified tumors, 25% for PLAGL2-amplified tumors, 18% for male patients, and 82% for female patients. In summary, we describe a new type of biologically distinct CNS tumor characterized by PLAGL1/2 amplification that occurs predominantly in infants and toddlers (PLAGL2) or adolescents (PLAGL1) which we consider best classified as a CNS embryonal tumor and which is associated with intermediate survival. The cell of origin and optimal treatment strategies remain to be defined.
PMID: 36437415
ISSN: 1432-0533
CID: 5383452
A nine-month-old boy with regression of milestones and severe constipation: an unusual case of a large spinal NTRK1 fusion pilocytic astrocytoma
Offenbacher, Rachel; Kobets, Andrew; Dalvi, Nagma; Hsu, Kevin; Chin, Steven; Snuderl, Matija; Levy, Adam; Martin, Allison
INTRODUCTION/BACKGROUND:Pilocytic astrocytoma, a World Health Organization grade 1 tumor, is the most common brain tumor in children between 5 and 14 years of age and the second most common in children younger than 5 and older than 14. Although classical to the cerebellum and hypothalamic regions, it can also arise in the spinal cord. Larotrectinib, a selective inhibitor of tropomyosin receptor kinase, has been effective in pediatric tumors with NTRK fusion mutations in children as young as 1-month-old. CASE/METHODS:We share the case of a 9-month-old boy who presented with a 4-month history of regression of his milestones and severe constipation who was found to have a large spinal pilocytic astrocytoma with multiple intracranial periventricular lesions.
PMID: 36107222
ISSN: 1433-0350
CID: 5336352
DNA damage drives DNA methylation and 3D chromatin organization alterations in glioblastoma [Meeting Abstract]
Modrek, Aram S.; Do, Catherine; Zhang, Zeyan; Deng, Yingwen; Karp, Jerome; Ezhilarasan, Ravesanker; Cova, Giulia; Snuderl, Matija; Tsirigos, Aristotelis; Skok, Jane; Sulman, Erik P.
ISI:000892509507561
ISSN: 0008-5472
CID: 5526672
ADAPTIVE RESPONSES TO GENOME-WIDE DNA DAMAGE RESULT IN TOPOLOGIC GENOME REORGANIZATION IN GLIOBLASTOMA [Meeting Abstract]
Modrek, Aram; Do, Catherine; Zhang, Zeyan; Deng, Yingwen; Karp, Jerome; Ezhilarasan, Ravesanker; Valor, Belen; Cova, Giulia; Jafari, Matiar; Snuderl, Matija; Tsirigos, Aristotelis; Skok, Jane; Sulman, Erik
ISI:000888571000458
ISSN: 1522-8517
CID: 5526662
Detection of gene fusions, cryptic rearrangements, and gene regulatory interactions in brain tumors by whole-genome Hi-C [Meeting Abstract]
Galbraith, Kristyn; Yang, Yiying; Mohamed, Hussein; Movahed-Ezazi, Misha; Tran, Ivy; Zeck, Briana; Chiriboga, Luis; Sikkink, Kristin; Schmitt, Anthony; Tsirigos, Aristotelis; Jour, George; Snuderl, Matija
ISI:000798368400105
ISSN: 0022-3069
CID: 5525632
RADIONUCLIDE THERAPY WITH 177LU-DOTATATE (LUTATHERA) IN ADULTS WITH ADVANCED INTRACRANIAL MENINGIO [Meeting Abstract]
Kurz, S; Zan, E; Cordova, C; Barbaro, M; Troxel, A; Silverman, J; Snuderl, M; Zagzag, D; Golfinos, J; Kondziolka, D; Sulman, E
BACKGROUND: While most meningiomas are considered benign tumors, a subset of these tumors are characterized by a more aggressive clinical course and require multimodal treatment. Beyond surgical and radiotherapeutic options, there are no effective medical treatments available. Somatostatin receptor 2 (SSTR2) is expressed by the majority of meningiomas. 177Lu-DOTATATE is a SSTR2-targeting radionuclide that has been successful in neuroendocrine tumors. Here we report the results of the interim analysis of an ongoing clinical trial (NCT03971461) that is evaluating the effect of 177Lu-DOTATATE in treating progressive intracranial meningiomas.
METHOD(S): In this Simon two-stage design phase II study, adults with advanced intracranial meningiomas received 177Lu-DOTATATE 7.4 GBq (200 mCi) every eight weeks for four doses. 68Ga-DOTATATE PET-MRI was performed before and at the end of treatment. The primary endpoint was progression-free survival at 6 months (PFS-6). Correlative studies evaluated the association of PFS-6, objective response rate, progression-free survival, overall survival with radiographic tumor measurements, 68Ga-DOTATATE uptake on PET-MRI, SSTR2 expression in tumor, and meningioma methylation subclass.
RESULT(S): Fourteen patients (F = 11, M = 3) with progressive meningiomas (WHO I = 3, II = 10, III = 1) have been enrolled. Median age was 63.1 (range 49-78) years. All patients previously underwent tumor resection and at least one course of radiation. Treatment with 177Lu-DOTATATE was well tolerated, no treatment-limiting toxicities were observed. Six of 14 patients (42%) achieved PFS-6. Radiographically, all six patients had achieved Stable Disease. A functional alteration of tumoral SSTR2 expression by 68Ga-DOTATATE PET-MR imaging was observed in three patients.
CONCLUSION(S): Treatment with SSTR2- targeting 177Lu-DOTATATE is well tolerated. In this interim analysis, six of 14 patients achieved PFS-6. This exceeds the predefined threshold to continue to stage two of this study. This clinical trial is now open to patient enrollment at two study sites in the US
EMBASE:639939893
ISSN: 1523-5866
CID: 5513302
Association of hyperglycemia and molecular subclass on survival in IDH-wildtype glioblastoma
Liu, Elisa K; Vasudevaraja, Varshini; Sviderskiy, Vladislav O; Feng, Yang; Tran, Ivy; Serrano, Jonathan; Cordova, Christine; Kurz, Sylvia C; Golfinos, John G; Sulman, Erik P; Orringer, Daniel A; Placantonakis, Dimitris; Possemato, Richard; Snuderl, Matija
BACKGROUND/UNASSIGNED:Hyperglycemia has been associated with worse survival in glioblastoma. Attempts to lower glucose yielded mixed responses which could be due to molecularly distinct GBM subclasses. METHODS/UNASSIGNED:Clinical, laboratory, and molecular data on 89 IDH-wt GBMs profiled by clinical next-generation sequencing and treated with Stupp protocol were reviewed. IDH-wt GBMs were sub-classified into RTK I (Proneural), RTK II (Classical) and Mesenchymal subtypes using whole-genome DNA methylation. Average glucose was calculated by time-weighting glucose measurements between diagnosis and last follow-up. RESULTS/UNASSIGNED:= .02). Methylation clustering did not identify unique signatures associated with high or low glucose levels. Metabolomic analysis of 23 tumors showed minimal variation across metabolites without differences between molecular subclasses. CONCLUSION/UNASSIGNED:Higher average glucose values were associated with poorer OS in RTKI and Mesenchymal IDH-wt GBM, but not RTKII. There were no discernible epigenetic or metabolomic differences between tumors in different glucose environments, suggesting a potential survival benefit to lowering systemic glucose in selected molecular subtypes.
PMCID:9653172
PMID: 36382106
ISSN: 2632-2498
CID: 5384812
DNA methylation-based classification of sinonasal tumors
Jurmeister, Philipp; Glöß, Stefanie; Roller, Renée; Leitheiser, Maximilian; Schmid, Simone; Mochmann, Liliana H; Payá Capilla, Emma; Fritz, Rebecca; Dittmayer, Carsten; Friedrich, Corinna; Thieme, Anne; Keyl, Philipp; Jarosch, Armin; Schallenberg, Simon; Bläker, Hendrik; Hoffmann, Inga; Vollbrecht, Claudia; Lehmann, Annika; Hummel, Michael; Heim, Daniel; Haji, Mohamed; Harter, Patrick; Englert, Benjamin; Frank, Stephan; Hench, Jürgen; Paulus, Werner; Hasselblatt, Martin; Hartmann, Wolfgang; Dohmen, Hildegard; Keber, Ursula; Jank, Paul; Denkert, Carsten; Stadelmann, Christine; Bremmer, Felix; Richter, Annika; Wefers, Annika; Ribbat-Idel, Julika; Perner, Sven; Idel, Christian; Chiariotti, Lorenzo; Della Monica, Rosa; Marinelli, Alfredo; Schüller, Ulrich; Bockmayr, Michael; Liu, Jacklyn; Lund, Valerie J; Forster, Martin; Lechner, Matt; Lorenzo-Guerra, Sara L; Hermsen, Mario; Johann, Pascal D; Agaimy, Abbas; Seegerer, Philipp; Koch, Arend; Heppner, Frank; Pfister, Stefan M; Jones, David T W; Sill, Martin; von Deimling, Andreas; Snuderl, Matija; Müller, Klaus-Robert; Forgó, Erna; Howitt, Brooke E; Mertins, Philipp; Klauschen, Frederick; Capper, David
The diagnosis of sinonasal tumors is challenging due to a heterogeneous spectrum of various differential diagnoses as well as poorly defined, disputed entities such as sinonasal undifferentiated carcinomas (SNUCs). In this study, we apply a machine learning algorithm based on DNA methylation patterns to classify sinonasal tumors with clinical-grade reliability. We further show that sinonasal tumors with SNUC morphology are not as undifferentiated as their current terminology suggests but rather reassigned to four distinct molecular classes defined by epigenetic, mutational and proteomic profiles. This includes two classes with neuroendocrine differentiation, characterized by IDH2 or SMARCA4/ARID1A mutations with an overall favorable clinical course, one class composed of highly aggressive SMARCB1-deficient carcinomas and another class with tumors that represent potentially previously misclassified adenoid cystic carcinomas. Our findings can aid in improving the diagnostic classification of sinonasal tumors and could help to change the current perception of SNUCs.
PMCID:9705411
PMID: 36443295
ISSN: 2041-1723
CID: 5373902